Overview

A First In Human Study Of PF-00184562 In Healthy Volunteers

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are: - To determine the safety, tolerability and pharmacokinetics of single doses of PF-00184562; and - To explore the exposure-response relationship of neuropsychometric and tolerability measures of PF-00184562 compared to olanzapine.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Collaborator:
PPD
Treatments:
Olanzapine